title: Removing a hair of doubt about BRAF targeting.
abstract: In this issue of Blood, Pettirossi et al, including Drs Tiacci and Falini, who led the effort in 2011 defining the BRAF-V600E driving mutation in hairy cell leukemia (HCL),provide extensive laboratory studies showing that inhibitors of BRAF-V600E and/or mitogen-activated protein kinase kinase (MEK) reach their targets and cause HCL cell death
authors.affiliation: NATIONAL INSTITUTES OF HEALTH.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Kreitman
mesh_terms: D000970:Antineoplastic Agents; D006801:Humans; D007093:Imidazoles; D007211:Indoles; D007943:Leukemia, Hairy Cell / Q000188:drug therapy* / Q000235:genetics*; D010091:Oximes; D011728:Pyridones; D011744:Pyrimidinones; D013449:Sulfonamides; D059467:Transcriptome / Q000187:drug effects*; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D007211:Indoles; D010091:Oximes; D011728:Pyridones; D011744:Pyrimidinones; D013449:Sulfonamides; D000077484:Vemurafenib; C560077:trametinib; C561627:dabrafenib